"Eli Lilly has impressive fundamentals, a solid drug pipeline, and an ability to thrive even if the overall market is falling. The company recently reported first quarter results and beat expectations."
"Despite the impressive numbers, the stock has dropped and lost 10% year-to-date. This dip is an amazing opportunity to buy. Earlier in 2022, the stock soared with the approval of the GLP-1 injectable, Mounjaro, and the rally hasn't stopped."
"Eli Lilly has recently received an approval for its next big growth driver, Foundayo, a weight-loss pill. Early results from its trials will give the stock a boost."
"The management has raised its full-year sales and profit outlook, showing confidence in the business."
Investors are worried about the stock market due to geopolitical tensions, inflation, and economic uncertainties. The S&P 500 has gained 5% this year, but a potential crash looms. Eli Lilly is highlighted as a strong healthcare stock with impressive fundamentals and a solid drug pipeline. Despite a 10% year-to-date drop, its revenue surged 56% to $19.8 billion, and EPS increased by 170%. The company has received approval for a weight-loss pill, Foundayo, and raised its sales and profit outlook, indicating strong growth potential.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]